(Q41648609)

6 October 2017

1 reference

title

Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin (English)

1 reference

6 October 2017

0 references

1 reference

Tartaglione T

1

1 reference

6 October 2017

publication date

1 July 1997

1 reference

6 October 2017

published in

Clinical Therapeutics

1 reference

6 October 2017

volume

19

1 reference

6 October 2017

issue

4

1 reference

6 October 2017

page(s)

626-38; discussion 603

1 reference

The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS)

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterium avium complex infection in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterium avium complex infection and AIDS: advances in theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterium kansasii: A Cause of Treatable Pulmonary Disease Associated with Advanced Human Immunodeficiency Virus (HIV) Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Kansas City AIDS Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Diagnosis and management of mycobacterial infection and disease in persons with human immunodeficiency virus infection. Centers for Disease Control, U.S. Department of Health and Human Services

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterial Diseases Other Than Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

In vitro susceptibility of Mycobacterium kansasii to clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Disseminated infection with rapidly growing mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Disseminated "Mycobacterium genavense" infection in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Infection with a fastidious Mycobacterium resembling Mycobacterium simiae in seven patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Mycobacterium genavense infection presenting as a solitary brain mass in a patient with AIDS: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

Cultural studies on two isolates of “Mycobacterium genavense” from patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980088-4

7 January 2021

10.1016/S0149-2918(97)80088-4

Identifiers

DOI

1 reference

release_qzgolkcqxbg53k4b5n67f3hehm

6 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qzgolkcqxbg53k4b5n67f3hehm

24 November 2022

mapped directly with Wikidata item

1 reference